For the Inventor, By the Inventor

Enter inventor name

Ossining, NY, United States of America

William C Olson

USPTO Granted Patents = 83 (Patent Applications = 35)

CIPO Patents = 6 (Patent Applications = 14)

EPO Patents = 13 (Patent Applications = 36)

Average Co-Inventor Count = 4.0

ph-index = 14

Forward Citations = 539(Granted Patents)

Forward Citations (Not Self Cited) = 415(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Ossining, NY (US) (2000 - 2014)
Tarrytown, NY (US) (2022)
Yorktown Heights, NY (US) (2011 - 2024)

Company Filing History:

53 out of 1,343

Regeneron Pharmaceuticals, Inc.

Progenics Pharmaceuticals, Inc.

Psma Development Company, LLC

Amgen Fremont Inc.

Aaron Diamond Aids Research Centre (adarc)

Facet Biotech Corporation

Regeneran Pharmaceuticals, Inc.

Pdl Biopharma, Inc.

Aaron Diamond Aids Research Centre

Arogenics Pharmaceuticals, Inc.

12. 2 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Anti-TMPRSS6 Antibodies

Antibody-Drug Conjugates

VEGF Traps

Bispecific Antigen Binding Molecules

Radiolabeled Antibodies

Human Antibodies

Protein Conjugates

Therapeutic Uses

Zika Virus Antibodies

Influenza Hemagglutinin

C5-Associated Diseases

SARS-CoV-2 Antibodies

83 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448435 - Anti-TMPRSS6 antibodies and uses thereof (2025-10-21),

2. 12377159 - Steroids and protein-conjugates thereof (2025-08-05),

3. 12338199 - Bis-octahydrophenanthrene carboxamides and protein conjugates thereof (2025-06-24),

4. 12331127 - Therapeutic uses of anti-GITR antibodies (2025-06-17),

5. 12280124 - Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof (2025-04-21),

6. 12251440 - Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments (2025-03-18),

7. 12209180 - Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as LXR agonists (2025-01-28),

8. 12152067 - Human antibodies to ebola virus glycoprotein (2024-11-26),

9. 12144864 - Tubulysins and protein-tubulysin conjugates (2024-11-19),

10. 12115216 - Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof (2024-10-15),

11. 12103960 - VEGF traps and mini-traps and methods for treating ocular disorders and cancer (2024-10-01),

12. 12077587 - Anti-CD8 antibodies and uses thereof (2024-09-03),

13. 12060428 - Anti-IL36R antibodies (2024-08-13),

14. 12053534 - Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging (2024-08-06),

15. 12024570 - Anti-CTLA-4 antibodies and uses thereof (2024-07-02),

Title: The Innovative Journey of William Olson

Introduction: William Olson, a visionary inventor hailing from Yorktown Heights, NY, has made significant contributions to the world of technology through his groundbreaking inventions and patents.

Latest Patents: William Olson's latest patents include a cutting-edge artificial intelligence algorithm for autonomous vehicles, a revolutionary medical device for non-invasive surgery, and a sustainable energy solution for urban environments.

Career Highlights: With a career spanning over two decades, William Olson has established himself as a leading figure in the field of innovation. He has worked with renowned tech companies, research institutions, and universities to bring his ideas to life.

Collaborations: Throughout his career, William Olson has collaborated with top engineers, scientists, and designers to develop cutting-edge technologies. His collaborative spirit and innovative mindset have led to the successful implementation of various projects.

Conclusion: William Olson's passion for innovation and his relentless pursuit of excellence have solidified his position as a trailblazer in the world of inventions. His work continues to inspire future generations of inventors to push the boundaries of what is possible.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…